| __timestamp | Merck & Co., Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16768000000 | 5903000 |
| Thursday, January 1, 2015 | 14934000000 | 2762000 |
| Friday, January 1, 2016 | 13891000000 | 1114000 |
| Sunday, January 1, 2017 | 12775000000 | 25573000 |
| Monday, January 1, 2018 | 13509000000 | 6000000 |
| Tuesday, January 1, 2019 | 14112000000 | 38845000 |
| Wednesday, January 1, 2020 | 13618000000 | 50523000 |
| Friday, January 1, 2021 | 13626000000 | 75463000 |
| Saturday, January 1, 2022 | 17411000000 | 105767000 |
| Sunday, January 1, 2023 | 16126000000 | 167512000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. Merck & Co., Inc., a titan in the field, has consistently maintained a high cost of revenue, averaging around $14.7 billion annually from 2014 to 2023. In contrast, Xenon Pharmaceuticals Inc., a smaller player, has seen its cost of revenue grow significantly, from a modest $5.9 million in 2014 to $167.5 million in 2023, marking a staggering increase of over 2700%.
While Merck's cost of revenue fluctuated slightly, peaking at $17.4 billion in 2022, Xenon's growth trajectory highlights its expanding operations and market presence. This comparison underscores the diverse strategies and scales of operation within the pharmaceutical sector. As Xenon continues to grow, it will be interesting to see how its cost structure evolves in the coming years.
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Cost Insights: Breaking Down Merck & Co., Inc. and Jazz Pharmaceuticals plc's Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Amneal Pharmaceuticals, Inc.
Merck & Co., Inc. or Xenon Pharmaceuticals Inc.: Who Invests More in Innovation?
Cost Insights: Breaking Down Merck & Co., Inc. and PTC Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Merck & Co., Inc. and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Xenon Pharmaceuticals Inc. vs Galapagos NV
Comparing Cost of Revenue Efficiency: Xenon Pharmaceuticals Inc. vs Viridian Therapeutics, Inc.